Combination Chemotherapy in Treating Women With Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
yet known whether doxorubicin plus docetaxel is more effective than doxorubicin plus
cyclophosphamide for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of doxorubicin in
combination with either docetaxel or cyclophosphamide in treating women who have previously
untreated, advanced, or inflammatory breast cancer.